These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37256863)

  • 1. Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation.
    Altcheh J; Moscatelli G; Caruso M; Moroni S; Bisio M; Miranda MR; Monla C; Vaina M; Valdez M; Moran L; Ramirez T; Patiño OL; Riarte A; Gonzalez N; Fernandes J; Alves F; Ribeiro I; Garcia-Bournissen F
    PLoS Negl Trop Dis; 2023 May; 17(5):e0010850. PubMed ID: 37256863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults.
    Altcheh J; Moscatelli G; Mastrantonio G; Moroni S; Giglio N; Marson ME; Ballering G; Bisio M; Koren G; García-Bournissen F
    PLoS Negl Trop Dis; 2014 May; 8(5):e2907. PubMed ID: 24853169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited infant exposure to benznidazole through breast milk during maternal treatment for Chagas disease.
    García-Bournissen F; Moroni S; Marson ME; Moscatelli G; Mastrantonio G; Bisio M; Cornou L; Ballering G; Altcheh J
    Arch Dis Child; 2015 Jan; 100(1):90-4. PubMed ID: 25210104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial.
    Molina-Morant D; Fernández ML; Bosch-Nicolau P; Sulleiro E; Bangher M; Salvador F; Sanchez-Montalva A; Ribeiro ALP; de Paula AMB; Eloi S; Correa-Oliveira R; Villar JC; Sosa-Estani S; Molina I
    Trials; 2020 Apr; 21(1):328. PubMed ID: 32293523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of benznidazole in adult patients with Chagas disease.
    Soy D; Aldasoro E; Guerrero L; Posada E; Serret N; Mejía T; Urbina JA; Gascón J
    Antimicrob Agents Chemother; 2015; 59(6):3342-9. PubMed ID: 25824212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
    Torrico F; Gascon J; Ortiz L; Alonso-Vega C; Pinazo MJ; Schijman A; Almeida IC; Alves F; Strub-Wourgaft N; Ribeiro I;
    Lancet Infect Dis; 2018 Apr; 18(4):419-430. PubMed ID: 29352704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
    Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole.
    Fernández ML; Marson ME; Ramirez JC; Mastrantonio G; Schijman AG; Altcheh J; Riarte AR; Bournissen FG
    Mem Inst Oswaldo Cruz; 2016 Mar; 111(3):218-21. PubMed ID: 26982179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benznidazole in Cerebrospinal Fluid: a Case Series of Chagas Disease Meningoencephalitis in HIV-Positive Patients.
    Fernández ML; Marson ME; Mastrantonio GE; Corti MA; Fleitas U; Lloveras SC; Lista N; Priarone MM; Domínguez C; Garcia-Bournissen F
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33361290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-17A, a possible biomarker for the evaluation of treatment response in Trypanosoma cruzi infected children: A 12-months follow-up study in Bolivia.
    Vásquez Velásquez C; Russomando G; Espínola EE; Sanchez Z; Mochizuki K; Roca Y; Revollo J; Guzman A; Quiroga B; Rios Morgan S; Vargas Ortiz R; Zambrana Ortega A; Espinoza E; Nishizawa JE; Kamel MG; Kikuchi M; Mizukami S; Na-Bangchang K; Tien Huy N; Hirayama K
    PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007715. PubMed ID: 31553732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).
    Altcheh J; Castro L; Dib JC; Grossmann U; Huang E; Moscatelli G; Pinto Rocha JJ; Ramírez TE;
    PLoS Negl Trop Dis; 2021 Jan; 15(1):e0008912. PubMed ID: 33412557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-Drug Interaction Study of Benznidazole and E1224 in Healthy Male Volunteers.
    Ribeiro I; Blum B; Fernandes J; Santina G; Asada M; Everson M; Schuck E; Feleder E; Evene E; Gualano V
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice.
    Perin L; Moreira da Silva R; Fonseca KD; Cardoso JM; Mathias FA; Reis LE; Molina I; Correa-Oliveira R; Vieira PM; Carneiro CM
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.
    Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ
    Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial.
    Torrico F; Gascón J; Barreira F; Blum B; Almeida IC; Alonso-Vega C; Barboza T; Bilbe G; Correia E; Garcia W; Ortiz L; Parrado R; Ramirez JC; Ribeiro I; Strub-Wourgaft N; Vaillant M; Sosa-Estani S;
    Lancet Infect Dis; 2021 Aug; 21(8):1129-1140. PubMed ID: 33836161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal follow up of serological response in children treated for Chagas disease.
    Moscatelli G; Moroni S; García Bournissen F; González N; Ballering G; Schijman A; Corral R; Bisio M; Freilij H; Altcheh J
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007668. PubMed ID: 31465522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.
    Yun O; Lima MA; Ellman T; Chambi W; Castillo S; Flevaud L; Roddy P; Parreño F; Albajar Viñas P; Palma PP
    PLoS Negl Trop Dis; 2009 Jul; 3(7):e488. PubMed ID: 19582142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.